Medica Group Announces Strategic Partnership with Hugel South Korea for the Distribution of Botulax, FDA-Approved Botulinum Toxin in the Middle East and Africa

Medica Group, a leading distributor of aesthetic and medical solutions across the Middle East and Africa, has announced its partnership with Hugel, South Korea’s leading medical aesthetic company. This strategic alliance will bring Botulax, Hugel’s renowned FDA and CE-marked botulinum toxin, to the Middle Eastern and African markets, providing healthcare professionals with a trusted, high-quality solution for medical aesthetics.

Botulax is a highly purified botulinum toxin type A product recognized for its superior safety, efficacy, and consistency. It is widely used to reduce the appearance of wrinkles and fine lines by temporarily relaxing targeted facial muscles. Its high-quality manufacturing standards and rigorous clinical testing ensure it delivers reliable, predictable outcomes, making it a preferred solution for minimally invasive cosmetic treatments.

Andre Daoud, CEO of Medica Group, highlighted the importance of this collaboration:
“Our partnership with Hugel marks a key milestone for us as we continue to expand our portfolio and lead the aesthetics market with global solutions. The introduction of Botulax in the Middle East and Africa offers healthcare professionals access to a world-class botulinum toxin that is highly trusted for its quality, safety, and performance. This strategic partnership aligns with our mission to provide advanced, innovative products and services that meet the demands of the region’s growing beauty and medical aesthetics market. Hugel’s global expertise, combined with our deep local knowledge and network, will create tremendous value for our customers and their patients.”

Suk Cha, Executive Chairman of Hugel, commented on the partnership: “We are very pleased to enter into this strategic collaboration with Medica Group. The Middle East represents a key market for Hugel, with its rapidly growing demand for medical aesthetic treatments. We have chosen Medica Group as our exclusive distributor because they share our commitment to excellence and quality. Their proven expertise, extensive reach, and deep understanding of the region make them the ideal partner to bring our Botulax product to this dynamic region. Botulax is recognized globally for its quality, and we are confident that, through this partnership, it will become a leading choice for medical professionals and patients in the Middle East and Africa.”